Pediatrix Medical Group Inc

Pediatrix Medical Group Inc(MD)股票分析

$27.380

-0.375 (-1.37%)收盘时

Loading chart…
最高
28.020
开盘
27.900
成交量加权均价
27.51
成交量
535.00K
市值
607.54M
最低
27.130
成交额
14.72M
企业价值/息税折旧摊销前利润(TTM)
8.84

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

AI 分析 of Pediatrix Medical Group Inc (MD)

持有

Pediatrix Medical Group Inc is currently trading at $27.38, which is close to the average analyst price target of $28. The stock has shown a strong year-to-date change of +28.60% and a one-year change of +62.20%, indicating solid performance. However, the RSI is at 65.946, suggesting that the stock may be approaching overbought territory. The main risk is the downgrade from Jefferies, which highlights potential earnings growth limitations due to enhanced tax credit headwinds.

分析师评级(14)

-14.17% 下跌空间
持有
3 买入
10 持有
1 卖出
当前: 27.38
最低
23.00
平均
23.50
最高
24.00

Jefferies

2026-08-19

目标价

$28

持有

UBS

2026-08-06

目标价

$28

中性

Deutsche Bank

2026-08-05

目标价

$25

持有

UBS

2026-05-12

目标价

$25

中性

Mizuho

2026-05-08

目标价

$24

中性

估值指标

Pediatrix Medical Group Inc(MD)当前预期市盈率为 9.29,5 年平均预期市盈率为 9.35。

预期市盈率

合理
5 年均值 P/E
9.35
当前P/E
9.29
高估
11.66
低估
7.04

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.02
当前EV/EBITDA
8.84
高估
9.65
低估
6.40

预期市销率

高估
5 年均值 P/S
0.71
当前P/S
1.12
高估
0.96
低估
0.47

Alphio AI 对 MD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MD

$14.32

情景价格

基

基准

基准 · 50%MD

$11.56

情景价格

悲

悲观

悲观 · 25%MD

$9.40

情景价格

持有 MD 的大户

D

Dana Investment Advisors Inc

+ 持有MD

+2.95%

3个月收益率

A

Applied Finance Advisors, LLC

+ 持有MD

-4.08%

3个月收益率

事件时间线

2026-08-04 (ET)

06:30:00

Company Reports Q2 Revenue of $487.8M, Exceeds Expectations

06:30:00

Pediatrix Medical Sees 2026 Adjusted EBITDA of $280M-$300M

2026-07-15 (ET)

07:00:00

Pediatrix Medical Group Confirms Stable Q2 2026 Business Trends

2026-05-05 (ET)

06:20:00

Pediatrix Medical Reaffirms FY26 Adjusted EBITDA View of $280M-$300M

06:10:00

Pediatrix Medical Group Q1 Revenue Reaches $476M

资讯

MD 常见问题 —— 由 Alphio AI 解答

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).

Pediatrix Medical Group Inc is currently trading at $27.38, which is close to the average analyst price target of $28. The stock has shown a strong year-to-date change of +28.60% and a one-year change of +62.20%, indicating solid performance. However, the RSI is at 65.946, suggesting that the stock may be approaching overbought territory. The main risk is the downgrade from Jefferies, which highlights potential earnings growth limitations due to enhanced tax credit headwinds.

14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易